Thr80 of sheep
podoplanin is a critical epitope of the anti-sheep podoplanin monoclonal
antibody, PMab-256
Yukinari Kato1,
2, Masato Sano1, Teizo Asano1, Yusuke Sayama1,
Mika K. Kaneko1
1Department of
Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1
Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan
2New Industry
Creation Hatchery Center, Tohoku University, 2-1, Seiryo-machi, Aoba-ku,
Sendai, Miyagi 980-8575, Japan
Address
correspondence to: Yukinari Kato; New Industry Creation
Hatchery Center, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi
980-8575, Japan; E-mail: yukinarikato@med.tohoku.ac.jp
Abstract
An anti-sheep podoplanin (sPDPN) monoclonal antibody (mAb),
PMab-256, has recently been established. PMab-256 shows positive immunostaining
for lymphatic endothelial cells (LECs), lung type I alveolar cells, and kidney podocytes.
PDPN possesses three platelet-aggregation-stimulating (PLAG) domains, PLAG1,
PLAG2, and PLAG3, and a PLAG-like domain (PLD). The binding epitope of many
anti-PDPN mAbs is located in PLAG domains or PLD. The purpose of the present study
is to determine the binding epitope of PMab-256. Analysis of sPDPN deletion
mutants revealed that the N-terminus of the PMab-256 epitope exists between
amino acids (aa) 75 and 80 of sPDPN. Further, analysis of sPDPN point mutations
demonstrated that the critical epitope includes Thr80 of sPDPN, indicating that
the PMab-256 epitope is in the PLD of sPDPN.
Key words: sheep podoplanin; monoclonal antibody; epitope, PMab-256
Introduction
Sensitive
and specific mAbs against podoplanin (PDPN) of various species including human (1), mouse (2), and whale (3) are necessary for the analysis of expression
and pathophysiological functions of PDPN. PDPN is used for discriminating
lymphatic endothelial cells (LECs) from vascular endothelial cells (4) or type I alveolar cells from type II
alveolar cells (5). An anti-sheep podoplanin (sPDPN) monoclonal
antibody (mAb), PMab-256, was obtained using the Cell-Based Immunization and Screening
(CBIS) method (6-8). Like other typical anti-PDPN mAbs, PMab-256
demonstrated positive immunoreaction for LECs (4), type I alveolar cells (5), and kidney podocytes (9).
The
binding epitope of many anti-PDPN mAbs is located in three platelet aggregation-stimulating
(PLAG) domains, PLAG1, PLAG2, and PLAG3, (10) at the N-terminus or a PLAG-like domain
(PLDs) (3, 11-14) in the middle of the PDPN protein. The purpose
of this study was to determine the binding epitope of PMab-256.
Materials and Methods
Cell
lines
Chinese hamster ovary (CHO)-K1 cells were obtained
from the American Type Culture Collection (Manassas, VA, USA). sPDPN mutation
plasmids containing a RAP14 tag (15) were transfected into CHO-K1 cells using
Lipofectamine LTX (Thermo Fisher Scientific Inc., Waltham, MA, USA). The RAP14
tag is comprised of 14 amino acids (aa), (DMVNPGLEDRIEDL),
and is recognized by PMab-2 mAb (16) and LpMab-7 (1). Cells transiently transfected with deletion
or point mutations were cultured in Roswell Park Memorial Institute (RPMI) 1640
medium (Nacalai Tesque, Inc., Kyoto, Japan), supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Thermo Fisher Scientific Inc.), 100
units/ml of penicillin, 100 μg/ml of streptomycin, and 25 μg/ml of amphotericin
B (Nacalai Tesque, Inc.) at 37°C in a humidified atmosphere of 5% CO2
and 95% air.
Production
of sPDPN mutants
Synthesized DNA (Eurofins Genomics KK, Tokyo, Japan) encoding sPDPN (Accession
No.: XM_004013802.4) was subcloned into the pCAG vector (FUJIFILM Wako Pure Chemical Corporation,
Osaka, Japan),
and a RAP14 tag was added at the N-terminus. Deletion mutants of the sPDPN
sequence were produced using a HotStar HiFidelity Polymerase Kit (Qiagen Inc.,
Hilden, Germany) with oligonucleotides. Substitutions of amino acids with alanine
in the sPDPN sequence were produced by QuikChange Lightning Site-Directed
Mutagenesis Kits (Agilent Technologies Inc., Santa Clara, CA, USA). PCR
fragments bearing desired mutations were inserted into the pCAG vector using
the In-Fusion HD Cloning Kit (Takara Bio, Inc., Shiga, Japan).
Flow
cytometry
Transiently transfected CHO-K1 cells were
detached by 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (EDTA; Nacalai
Tesque, Inc.) and collected using 10% FBS in RPMI 1640 medium. After washing
with 0.1% bovine serum albumin in phosphate-buffered saline, cells were
incubated with anti-sPDPN antibody (PMab-256; 1 μg/ml) and an anti-RAP14 tag
antibody (PMab-2; 1 μg/ml or LpMab-7; 1 μg/ml) for 30 min at 4°C. Alexa Fluor
488-conjugated anti-mouse IgG (1:2000; Cell Signaling Technology, Inc.,
Danvers, MA, USA) was added to each cell suspension and incubation continued
for 30 min at 4°C. Fluorescence data were collected and analyzed using a Cell
Analyzer EC800 (Sony Corp., Tokyo, Japan).
Results
Seven
deletion mutants of sPDPN in CHO-K1 cells, namely: dN30, with aa 30–168
deletion; dN40, aa 40–168; dN50, aa 50–168; dN60, aa 60–168; dN70, aa 70–168;
dN75, aa 75–168; dN80, aa 80–168; or wild type (WT) sPDPN, aa 27–168. All
deletion mutants and WT containing the N-terminal RAP14 tag were recognized by PMab-2
or LpMab-7 (anti-RAP14 tag mAbs), indicating that the expression level of each
construct is high (Fig. 1A). PMab-256 recognized dN30, dN40, dN50, dN60, dN70,
and dN75, but not dN80 (Fig. 1B), suggesting that the N-terminus of the PMab-256
epitope exists between sPDPN aa 75 and 80.
Next, a
series of point mutants of sPDPN: G75A, E76A, D77A, L78A, P79A, T80A, A81G, E82A,
S83A, T84A, T85A, and A86G were obtained. PMab-2 and LpMab-7 reacted with all
point mutants (Fig. 2A). By contrast, PMab-256 did not react with T80A (Fig. 2B).
Thr80 of sPDPN is essential for PMab-256 binding (Fig. 3).
Discussion
A
variety of mAbs against pig (17, 18), horse (19, 20), Tasmanian devil (21), alpaca (22), tiger (23), whale (24), goat (25, 26), bear (27, 28), and sheep (29) PDPNs using the CBIS method are available (6-8). An anti-sPDPN mAb PMab-256 is useful for
immunohistochemical analyses using FFPE tissues of sheep for detecting LECs of
many organs, type I alveolar cells, and renal epithelial cells (29). PMab-256 is also useful for western blot
analysis, indicating that PMab-256 recognizes sPDPN that is fixed in formalin and
denatured by SDS. Further, PMab-256 detects sPDPN in flow cytometry.
PLAG and
PLD domains bind C-type lectin-like receptor-2 (CLEC-2), and induce platelet
aggregation and cancer metastasis (30). Anti-PDPN mAbs, epitopes of which are
located in PLAG domains or PLD, could neutralize platelet aggregation (30). The epitope of PMab-256 is also located in PLD
of sPDPN. PMab-256 is thus not only a useful mAb for research but also could be
a functional mAb with the ability to neutralize induction of platelet aggregation.
Conflict of Interest
The authors have no conflict of interest.
Acknowledgments
This research was supported
in part by
AMED under Grant Numbers: JP20am0401013 (Y.K.), JP20am0101078
(Y.K.), and JP20ae0101028 (Y.K.), and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and
Grant Number 19K07705 (Y.K.).
References
1. Kato Y, Kaneko MK: A cancer-specific
monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci.
Rep. 2014;4:5924.
2. Yamada S, Itai S, Kaneko MK, Konnai S, Kato Y: Epitope
mapping of anti-mouse podoplanin monoclonal antibody PMab-1. Biochem Biophys
Rep. 2018;15:52-56.
3. Sayama Y, Sano M, Kaneko MK, Kato Y: Epitope Analysis of an
Anti-Whale Podoplanin Monoclonal Antibody, PMab-237, Using Flow Cytometry.
Monoclon Antib Immunodiagn Immunother. 2020.
4. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R,
Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki
D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic
capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J.
Pathol. 1999;154:385-394.
5. Rishi AK, Joyce-Brady M, Fisher J, Dobbs LG, Floros J,
VanderSpek J, Brody JS, Williams MC: Cloning, characterization, and development
expression of a rat lung alveolar type I cell gene in embryonic endodermal and
neural derivatives. Dev. Biol. 1995;167:294-306.
6. Itai S, Fujii Y, Nakamura T, Chang YW, Yanaka M, Saidoh N,
Handa S, Suzuki H, Harada H, Yamada S, Kaneko MK, Kato Y: Establishment of
CMab-43, a Sensitive and Specific Anti-CD133 Monoclonal Antibody, for
Immunohistochemistry. Monoclon Antib Immunodiagn Immunother. 2017;36:231-235.
7. Yamada S, Itai S, Nakamura T, Yanaka M, Chang YW, Suzuki H,
Kaneko MK, Kato Y: Monoclonal Antibody L1Mab-13 Detected Human PD-L1 in Lung
Cancers. Monoclon. Antib. Immunodiagn. Immunother. 2018;37:110-115.
8. Yamada S, Itai S, Nakamura T, Yanaka M, Kaneko MK, Kato Y:
Detection of high CD44 expression in oral cancers using the novel monoclonal
antibody, C44Mab-5. Biochem Biophys Rep. 2018;14:64-68.
9. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P,
Poczewski H, Kalt R, Schaffner G, Kerjaschki D: Podoplanin, novel 43-kd
membrane protein of glomerular epithelial cells, is down-regulated in puromycin
nephrosis. Am. J. Pathol. 1997;151:1141-1152.
10. Kaneko MK, Kato Y, Kitano T, Osawa M: Conservation of a
platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing
factor. Gene. 2006;378:52-57.
11. Kato Y, Sayama Y, Sano M, Kaneko MK: Epitope Analysis of an
Antihorse Podoplanin Monoclonal Antibody PMab-219. Monoclon Antib Immunodiagn
Immunother. 2019;38:266-270.
12. Kato Y, Takei J, Furusawa Y, Sayama Y, Sano M, Konnai S,
Kobayashi A, Harada H, Takahashi M, Suzuki H, Yamada S, Kaneko MK: Epitope
Mapping of Anti-Bear Podoplanin Monoclonal Antibody PMab-247. Monoclon Antib
Immunodiagn Immunother. 2019;38:230-233.
13. Sano M, Kaneko MK, Kato Y: Epitope Mapping of Monoclonal
Antibody PMab-233 Against Tasmanian Devil Podoplanin. Monoclon Antib
Immunodiagn Immunother. 2019;38:261-265.
14. Sayama Y, Sano M, Furusawa Y, Kaneko MK, Kato Y: Epitope
Mapping of PMab-225 an Anti-Alpaca Podoplanin Monoclonal Antibody Using Flow
Cytometry. Monoclon Antib Immunodiagn Immunother. 2019;38:255-260.
15. Kato Y, Yamada S, Itai S, Kobayashi A, Konnai S, Kaneko MK:
Immunohistochemical Detection of Sheep Podoplanin Using an Antibovine
Podoplanin Monoclonal Antibody PMab-44. Monoclon. Antib. Immunodiagn.
Immunother. 2018;37:265-268.
16. Oki H, Honma R, Ogasawara S, Fujii Y, Liu X, Takagi M, Kaneko
MK, Kato Y: Development of Sensitive Monoclonal Antibody PMab-2 Against Rat
Podoplanin. Monoclon. Antib. Immunodiagn. Immunother. 2015;34:396-403.
17. Kato Y, Yamada S, Furusawa Y, Itai S, Nakamura T, Yanaka M,
Sano M, Harada H, Fukui M, Kaneko MK: PMab-213: a monoclonal antibody for
immunohistochemical analysis against pig podoplanin. Monoclon. Antib.
Immunodiagn. Immunother. 2019;38:18-24.
18. Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M,
Fukui M, Harada H, Mizuno T, Sakai Y, Takasu M, Kaneko MK, Kato Y: PMab-210: A
Monoclonal Antibody Against Pig Podoplanin Monoclon. Antib. Immunodiagn.
Immunother. 2019;38:30-36.
19. Furusawa Y, Yamada S, Itai S, Sano M, Nakamura T, Yanaka M,
Handa S, Mizuno T, Maeda K, Fukui M, Harada H, Kaneko MK, Kato Y: Establishment
of Monoclonal Antibody PMab-202 Against Horse Podoplanin. Monoclon. Antib.
Immunodiagn. Immunother. 2018;37:233-237.
20. Kato Y, Yamada S, Itai S, Kobayashi A, Konnai S, Kaneko MK:
Anti-Horse Podoplanin Monoclonal Antibody PMab-219 is Useful for Detecting
Lymphatic Endothelial Cells by Immunohistochemical Analysis. Monoclon. Antib.
Immunodiagn. Immunother. 2018;37:272-274.
21. Furusawa Y, Yamada S, Itai S, Nakamura T, Takei J, Sano M,
Harada H, Fukui M, Kaneko MK, Kato Y: Establishment of a monoclonal antibody
PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin.
Biochem Biophys Rep. 2019;18:100631.
22. Kato Y, Furusawa Y, Yamada S, Itai S, Takei J, Sano M, Kaneko
MK: Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin
for immunohistochemical analyses. Biochem Biophys Rep. 2019;18:100633.
23. Furusawa Y, Kaneko MK, Nakamura T, Itai S, Fukui M, Harada H,
Yamada S, Kato Y: Establishment of a Monoclonal Antibody PMab-231 for Tiger
Podoplanin. Monoclon Antib Immunodiagn Immunother. 2019;38:89-95.
24. Kato Y, Furusawa Y, Itai S, Takei J, Nakamura T, Sano M,
Harada H, Yamada S, Kaneko MK: Establishment of an Anticetacean Podoplanin
Monoclonal Antibody PMab-237 for Immunohistochemical Analysis. Monoclon. Antib.
Immunodiagn. Immunother. 2019;38:108–113.
25. Furusawa Y, Yamada S, Nakamura T, Sano M, Sayama Y, Itai S,
Takei J, Harada H, Fukui M, Kaneko MK, Kato Y: PMab-235: A monoclonal antibody
for immunohistochemical analysis against goat podoplanin. Heliyon.
2019;5:e02063.
26. Takei J, Itai S, Harada H, Furusawa Y, Miwa T, Fukui M,
Nakamura T, Sano M, Sayama Y, Yanaka M, Handa S, Hisamatsu K, Nakamura Y,
Yamada S, Kaneko K, M., Kato Y: Characterization of Anti-Goat Podoplanin
Monoclonal Antibody PMab-235 Using Immunohistochemistry Against Goat Tissues.
Monoclon. Antib. Immunodiagn. Immunother.
2019;https://doi.org/10.1089/mab.2019.0022.
27. Takei J, Furusawa Y, Yamada S, Nakamura T, Sayama Y, Sano M,
Konnai S, Kobayashi A, Harada H, Kaneko MK, Kato Y: PMab-247 Detects Bear
Podoplanin in Immunohistochemical Analysis. Monoclon Antib Immunodiagn
Immunother. 2019;38:171-174.
28. Takei J, Yamada S, Konnai S, Ishinazaka T, Shimozuru M, Kaneko
MK, Kato Y: PMab-241 Specifically Detects Bear Podoplanin of Lymphatic
Endothelial Cells in the Lung of Brown Bear. Monoclon Antib Immunodiagn
Immunother. 2019;38:282-284.
29. Kato Y, Furusawa Y, Sano M, Takei J, Nakamura T, Yanaka M,
Okamoto S, Handa S, Komatsu Y, Asano T, Sayama Y, Kaneko MK: Development of an
Anti-Sheep Podoplanin Monoclonal Antibody PMab-256 for Immunohistochemical
Analysis of Lymphatic Endothelial Cells. Monoclon. Antib. Immunodiagn.
Immunother. in press.
30. Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S,
Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H:
Molecular analysis of the pathophysiological binding of the platelet
aggregation-inducing factor podoplanin to the C-type lectin-like receptor
CLEC-2. Cancer Sci. 2008;99:54-61.
Figure Legends
Figure 1. Epitope mapping of PMab-256 using deletion
mutations. (A) Deletion mutants
of sPDPN were analyzed using flow cytometry. Mutants were incubated with PMab-2
(anti-RAP14 tag mAb; red line) or buffer control (black line) for 30 min at
4°C, followed by staining with secondary antibodies. (B) Deletion mutants of sPDPN were analyzed using flow cytometry.
Mutants were incubated with LpMab-7
(anti-RAP14 tag mAb; red line) or buffer control (black line) for 30 min at
4°C, followed by staining with secondary antibodies. (C) Deletion mutants of sPDPN were analyzed using flow cytometry.
Mutants were incubated with PMab-256
(anti-sPDPN mAb; red line) or buffer control (black line) for 30 min at 4°C,
followed by staining with secondary antibodies. sPDPN, sheep podoplanin.
Figure 2. Epitope
mapping of PMab-256 using point mutations. (A) Transient point mutants expressing G75A, E76A, D77A, L78A, P79A,
T80A, A81G, E82A, S83A, T84A, T85A, and A86G of sPDPN were incubated with
PMab-2 (anti-RAP14 tag; red line), or buffer control (black line) for 30 min at
4°C, followed by staining with secondary antibodies. (B) Transient point mutants expressing G75A, E76A, D77A, L78A, P79A,
T80A, A81G, E82A, S83A, T84A, T85A, and A86G of sPDPN were incubated with
LpMab-7 (anti-RAP14 tag; red line) or buffer control (black line) for 30 min at
4°C, followed by staining with secondary antibodies. (C) Transient point mutants expressing G75A, E76A, D77A, L78A, P79A,
T80A, A81G, E82A, S83A, T84A, T85A, and A86G of sPDPN were incubated with
PMab-256 (anti-sPDPN mAb; red line) or buffer control (black line) for 30 min
at 4°C, followed by staining with secondary antibodies. sPDPN, sheep
podoplanin.
Figure 3. Schematic
illustration of the epitope recognized by PMab-256. (A) Illustration of WT sPDPN and its seven deletion mutants: dN30,
dN40, dN50, dN60, dN70, dN75, and dN80. Black bars: positive reactions of
PMab-256. White bars: negative reactions of PMab-256. WT, wild type. (B) A red amino acid indicates a
critical epitope of PMab-256. PLD, PLAG-like domain.



0 Comments